FDA Patches Error in Teva Generic Drug Yank
Published Date: 8/4/2025
Notice
Summary
The FDA fixed a previous announcement about Teva Pharmaceuticals pulling approval for 23 generic drug applications. This means some medicines made by Teva and others won’t be officially approved anymore, affecting patients and pharmacies. The correction clears up important details about when these changes happen and what it means for everyone involved.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
23 Generic Drug Approvals Withdrawn
The FDA corrected a notice that says approval was withdrawn for 23 abbreviated new drug applications. This means some medicines made by Teva Pharmaceuticals and others will no longer be officially approved, which can affect patients who take those drugs and pharmacies that dispense them. The correction clarifies timing and what the withdrawal means for everyone involved (notice originally published January 15, 2025).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-14680, Proposed Submission of Information Collection for OMB Review; Comment Request; Annual Reporting (Form 5500 Series)
The Pension Benefit Guaranty Corporation (PBGC) wants to keep collecting yearly reports from pension plans to make sure everything’s on track. This affects companies and organizations that manage retirement plans, and they’re asking for your thoughts before the current approval expires in March 2026. No big changes or extra costs are planned, just a smooth continuation of the reporting process.
Next: 2025-14683, Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications
The FDA is officially pulling the plug on 39 drug approvals because the companies told them these medicines aren’t being sold anymore. This means those drugs won’t be available, and the companies won’t have to keep up with approval rules. If you’re a patient or pharmacist, don’t expect these drugs back anytime soon!